Abstract
Drug-induced liver injury is a major reason for safety-related attrition in the pharmaceutical industry. There is continued search for in vitro models that can be used to consistently and reliably select compounds with reduced liability for liver injury. 2D in vitro models, such as liver cell lines and primary hepatocytes have been used for many decades prior to advancement to micropatterned 2D liver models; the latter have improved metabolic activity and can be cultured for long periods without loss of function/viability. The emergence of 3D liver models, including spheroids, 3D bioprinted livers, and liver-on-chip have the potential to revolutionize in vitro liver toxicity testing. These models have been collectively coined as microphysiological systems (MPS). The MPS models can be maintained in culture for at least 1-month during which they retain significant drug metabolism capability. Some MPS models can also be cocultured with other nonparenchymal supporting cells, such as endothelial, Kupffer, and stellate cells, which increases the versatility of the models for toxicity assessment. An added benefit of some MPS models is the ability to sample supernatant for biomarker measurements. There are several contexts of use for which MPS models can be applied, and the most likely use will be for candidate drug screening and mechanistic studies.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Tujios S, Fontana RJ (2011) Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 8(4):202–211. https://doi.org/10.1038/nrgastro.2011.22
Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwakar JA, Network D (2014) Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147(1):96–108. e104. https://doi.org/10.1053/j.gastro.2014.03.045
Fontana RJ (2014) Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 146(4):914–928. https://doi.org/10.1053/j.gastro.2013.12.032
Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna JG (2014) A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol Sci 137(1):189–211. https://doi.org/10.1093/toxsci/kft223
Soltanpour Y, Hilgendorf C, Ahlstrom MM, Foster AJ, Kenna JG, Petersen A, Ungell AL (2012) Characterization of THLE-cytochrome P450 (P450) cell lines: gene expression background and relationship to P450-enzyme activity. Drug Metab Dispos 40(11):2054–2058. https://doi.org/10.1124/dmd.112.045815
Dambach DM, Andrews BA, Moulin F (2005) New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol 33(1):17–26. https://doi.org/10.1080/01926230590522284
O’Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80(9):580–604. https://doi.org/10.1007/s00204-006-0091-3
Schadt S, Simon S, Kustermann S, Boess F, McGinnis C, Brink A, Lieven R, Fowler S, Youdim K, Ullah M, Marschmann M, Zihlmann C, Siegrist YM, Cascais AC, Di Lenarda E, Durr E, Schaub N, Ang X, Starke V, Singer T, Alvarez-Sanchez R, Roth AB, Schuler F, Funk C (2015) Minimizing DILI risk in drug discovery – a screening tool for drug candidates. Toxicol In Vitro 30(1 Pt B):429–437. https://doi.org/10.1016/j.tiv.2015.09.019
Shah F, Leung L, Barton HA, Will Y, Rodrigues AD, Greene N, Aleo MD (2015) Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays. Toxicol Sci 147(2):500–514. https://doi.org/10.1093/toxsci/kfv152
Otieno MA, Snoeys J, Lam W, Ghosh A, Player MR, Pocai A, Salter R, Simic D, Skaggs H, Singh B, Heng-Keang L (2017) Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury (DILI). Toxicol Sci. https://doi.org/10.1093/toxsci/kfx040
Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 25(8):1616–1632. https://doi.org/10.1021/tx300091x
Lauschke VM, Hendriks DF, Bell CC, Andersson TB, Ingelman-Sundberg M (2016) Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chem Res Toxicol 29(12):1936–1955. https://doi.org/10.1021/acs.chemrestox.6b00150
Shulman M, Nahmias Y (2013) Long-term culture and coculture of primary rat and human hepatocytes. Methods Mol Biol 945:287–302. https://doi.org/10.1007/978-1-62703-125-7_17
Wortelboer HM, de Kruif CA, van Iersel AA, Falke HE, Noordhoek J, Blaauboer BJ (1990) The isoenzyme pattern of cytochrome P450 in rat hepatocytes in primary culture, comparing different enzyme activities in microsomal incubations and in intact monolayers. Biochem Pharmacol 40(11):2525–2534
Kemp DC, Zamek-Gliszczynski MJ, Brouwer KL (2005) Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 83(2):207–214. https://doi.org/10.1093/toxsci/kfi020
Trask OJ Jr, Moore A, LeCluyse EL (2014) A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis. Assay Drug Dev Technol 12(1):16–27. https://doi.org/10.1089/adt.2013.525
Lin C, Khetani SR (2016) Advances in engineered liver models for investigating drug-induced liver injury. Biomed Res Int 2016:1829148. https://doi.org/10.1155/2016/1829148
Ware BR, Berger DR, Khetani SR (2015) Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol Sci 145(2):252–262. https://doi.org/10.1093/toxsci/kfv048
Goldring C, Antoine DJ, Bonner F, Crozier J, Denning C, Fontana RJ, Hanley NA, Hay DC, Ingelman-Sundberg M, Juhila S, Kitteringham N, Silva-Lima B, Norris A, Pridgeon C, Ross JA, Young RS, Tagle D, Tornesi B, van de Water B, Weaver RJ, Zhang F, Park BK (2017) Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. Hepatology 65(2):710–721. https://doi.org/10.1002/hep.28886
Xia L, Hong X, Sakban RB, Qu Y, Singh NH, McMillian M, Dallas S, Silva J, Sensenhauser C, Zhao S, Lim HK, Yu H (2016) Cytochrome P450 induction response in tethered spheroids as a three-dimensional human hepatocyte in vitro model. J Appl Toxicol 36(2):320–329. https://doi.org/10.1002/jat.3189
Wang Z, Luo X, Anene-Nzelu C, Yu Y, Hong X, Singh NH, Xia L, Liu S, Yu H (2015) HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening. J Appl Toxicol 35(8):909–917. https://doi.org/10.1002/jat.3090
Sirenko O, Hancock MK, Hesley J, Hong D, Cohen A, Gentry J, Carlson CB, Mann DA (2016) Phenotypic characterization of toxic compound effects on liver spheroids derived from iPSC using confocal imaging and three-dimensional image analysis. Assay Drug Dev Technol 14(7):381–394. https://doi.org/10.1089/adt.2016.729
Berger B, Donzelli M, Maseneni S, Boess F, Roth A, Krahenbuhl S, Haschke M (2016) Comparison of liver cell models using the Basel phenotyping cocktail. Front Pharmacol 7:443. https://doi.org/10.3389/fphar.2016.00443
Takahashi Y, Hori Y, Yamamoto T, Urashima T, Ohara Y, Tanaka H (2015) 3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells. Biosci Rep 35(3). https://doi.org/10.1042/BSR20150034
Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, Fredriksson Puigvert L, Dankers AC, Jacobs F, Snoeys J, Sison-Young RL, Jenkins RE, Nordling A, Mkrtchian S, Park BK, Kitteringham NR, Goldring CE, Lauschke VM, Ingelman-Sundberg M (2016) Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep 6:25187. https://doi.org/10.1038/srep25187
Okudaira T, Amimoto N, Mizumoto H, Kajiwara T (2016) Formation of three-dimensional hepatic tissue by the bottom-up method using spheroids. J Biosci Bioeng 122(2):213–218
Zhang GL, Fisher JP, Leong KW (2015) 3D bioprinting and nanotechnology in tissue engineering and regenerative medicine. Elsevier, London
Murphy SV, Atala A (2014) 3D bioprinting of tissues and organs. Nat Biotechnol 32(8):773–785. https://doi.org/10.1038/nbt.2958
Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, Roth AB (2016) Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS One 11(7):e0158674. https://doi.org/10.1371/journal.pone.0158674
Hanumegowda UM, Wu Y, Smith TR, Lehman-McKeeman L (2016) Monocrotaline toxicity in 3D-bioprinted human liver tissues. The Toxicologist, Supplement to Toxicological Sciences 150(1)
Norona LM, Nguyen DG, Gerber DA, Presnell SC, LeCluyse EL (2016) Editor’s highlight: modeling compound-induced fibrogenesis in vitro using three-dimensional bioprinted human liver tissues. Toxicol Sci 154(2):354–367. https://doi.org/10.1093/toxsci/kfw169
Bhatia SN, Ingber DE (2014) Microfluidic organs-on-chips. Nat Biotechnol 32(8):760–772. https://doi.org/10.1038/nbt.2989
Ingber DE (2016) Reverse engineering human pathophysiology with organs-on-chips. Cell 164(6):1105–1109. https://doi.org/10.1016/j.cell.2016.02.049
Vernetti LA, Senutovitch N, Boltz R, DeBiasio R, Shun TY, Gough A, Taylor DL (2016) A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med 241(1):101–114. https://doi.org/10.1177/1535370215592121
Senutovitch N, Vernetti L, Boltz R, DeBiasio R, Gough A, Taylor DL (2015) Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med 240(6):795–808. https://doi.org/10.1177/1535370215584934
Hamilton G (2017) Organs-on-chips: 3D microphysiological systems for understanding mechanism of action in drug discovery and development. The Toxicologist, Supplement to Toxicological Sciences: Abstract #2350
Church RJ, Watkins PB (2017) The transformation in biomarker detection and management of drug-induced liver injury. Liver Int. https://doi.org/10.1111/liv.13441
Acknowledgments
The authors acknowledge the Innovation and Quality (IQ) Microphysiological (MPS) Working Group members and the participation of Brett Howell of DILIsym, Inc. and Paul Watkins of University of North Carolina in discussions on MPS standards for liver models.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Otieno, M.A., Gan, J., Proctor, W. (2018). Status and Future of 3D Cell Culture in Toxicity Testing. In: Chen, M., Will, Y. (eds) Drug-Induced Liver Toxicity. Methods in Pharmacology and Toxicology. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-7677-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7677-5_12
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-7676-8
Online ISBN: 978-1-4939-7677-5
eBook Packages: Springer Protocols